Sihuan pharmaceutical acquires 27.82% equity of Duoduo pharmaceutical
-
Last Update: 2019-03-26
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In the evening of March 25, Zhongguancun announced that Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd (hereinafter referred to as "Sihuan pharmaceutical"), a wholly-owned subsidiary, intends to acquire 27.82% equity of Duoduo Pharmaceutical Co., Ltd (hereinafter referred to as "Duoduo pharmaceutical") held by Heilongjiang Nongken Jiaduo enterprise management service center (hereinafter referred to as "Nongken Jiaduo") Through consultation between Sihuan pharmaceutical and Heilongjiang Jiajian enterprise management consulting service partnership (hereinafter referred to as Heilongjiang Jiajian), Sihuan pharmaceutical transferred its 9.56% equity in Duoduo pharmaceutical industry to Heilongjiang Jiajian with 84.74 million yuan After the transfer, Sihuan pharmaceutical held 69.26% equity in Duoduo pharmaceutical industry and is still the controlling shareholder The relevant equity transfer agreement was signed in March 2019 The following is the original announcement:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
